Thermo Fisher raises guidance on 'fabulous' biopharma services growth

By Dan Stanton contact

- Last updated on GMT

Thermo Fisher is at “the end of the first quarter with three quarters to go,” CEO Marc Casper said describing potential growth in biopharma services
Thermo Fisher is at “the end of the first quarter with three quarters to go,” CEO Marc Casper said describing potential growth in biopharma services
The biopharma services market keeps expanding and “growth prospects look fabulous,” says Thermo Fisher, reporting better than expected sales across its Life Sciences business for the second quarter 2014.

For Q2 2014, Thermo Fisher’s Life Sciences Solutions business revenues shot up 500% year-on-year to $1.1bn (€820m) due primarily to the incorporation of Life Technologies, which the firm acquired for $13.6bn​ in February this year.

The integration process is going well with “synergies tracking ahead of plan,”​ the company said.

The Life Sciences Solutions unit now accounts for just over 25% of the company’s total revenue and growing demand for biopharma services has led to a slight increase in Thermo Fisher’s growth outlook for the full-year, CEO Marc Casper said in a conference call.

“Biopharma service is a great business,”​ he told investors (transcript here​). “It’s been doing great for a long period of time, and continues to do well,” ​with pharma firms continuing to outsource to Thermo Fisher as “the low-cost, high-quality provider.”

When asked about the penetration rate of the biopharma business, Casper said it was hard to give a figure as both Thermo Fisher’s customer base and its service offerings are expanding.

“We continue to add service lines but we’ve had customers say you do this so well, we like you to do syringe work with us, where we might have been doing other types of outsourcing works,”​ he said. “We just did our strategic plan review, which is a five year outlook for that business, and growth prospects look fabulous.”

When pushed as to how much the biopharma business could grow, Casper described the firm as at “the end of the first quarter with three quarters to go”​ in a nod to the upcoming American Football season.

The quarter also saw the company commence expansion at its Centres of Excellence in Vilnius, Lithuania and Bremen, Germany, adding manufacturing capacity to support growth of molecular biology products for life sciences and diagnostics.

Related news

Show more

Related products

An Intense Focus on Perfusion

An Intense Focus on Perfusion

MilliporeSigma | 09-Oct-2017 | Technical / White Paper

Continuous manufacturing technologies are seeing increased industry uptake, particularly perfusion systems and, increasingly, intensified perfusion. Perfusion...

A Trusted Resin Provider For Over 35 Years

A Trusted Resin Provider For Over 35 Years

Purolite Life Sciences | 18-Sep-2017

Watch our video above to learn more about the history of Purolite Life Sciences.To discuss how we can assist your journey to process excellence, please...

The Next Stage – Eppendorfs new Mastercycler X50

The Next Stage – Eppendorfs new Mastercycler X50

Eppendorf for Bioprocess – Solutions that grow with you | 05-Sep-2017 | Application Note

The Mastercycler X50 is Eppendorf's new PCR cycler with lots of new benefits. Not only can you heat with 10°C/s, you can also optimize two different...

Survey Report: State of the Biopharmaceutical Industry 2016

Survey Report: State of the Biopharmaceutical Industry 2016

William Reed Business Media: Publish your Technical Paper on this Website | 14-Jun-2016 | Insight Guide

In May 2016, BioPharma-Reporter conducted its inaugural ‘state of the industry’ survey. The key objective of the poll was to gauge views about the current...

Related suppliers